Cohort profile: the STOP HIV/AIDS Program Evaluation (SHAPE) study in British Columbia, Canada.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
12 05 2020
Historique:
entrez: 15 5 2020
pubmed: 15 5 2020
medline: 16 2 2021
Statut: epublish

Résumé

The Seek and Treat for Optimal Prevention of HIV/AIDS (STOP HIV/AIDS) Program Evaluation (SHAPE) study is a longitudinal cohort developed to monitor the progress of an HIV testing and treatment expansion programme across the province of British Columbia (BC). The study considers how sociostructural determinants such as gender, age, sexual identity, geography, income and ethnicity influence engagement in HIV care. Between January 2016 and September 2018, 644 BC residents who were at least 19 years old and diagnosed with HIV were enrolled in the study and completed a baseline survey. Participants will complete two additional follow-up surveys (18 months apart) about their HIV care experiences, with clinical follow-up ongoing. Analyses on baseline data have found high levels of HIV care engagement and treatment success among SHAPE participants, with 95% of participants receiving antiretroviral therapy and 90% having achieved viral suppression. However, persistent disparities in HIV treatment outcomes related to age, injection drug use and housing stability have been identified and require further attention when delivering services to marginalised groups. Our research will examine how engagement in HIV care evolves over time, continuing to identify barriers and facilitators for promoting equitable access to treatment and care among people living with HIV. A qualitative research project, currently in the formative phase, will compliment quantitative analyses by taking a strengths-based approach to exploring experiences of engagement and re-engagement in HIV treatment among individuals who have experienced delayed treatment initiation or treatment interruptions.

Identifiants

pubmed: 32404387
pii: bmjopen-2019-033649
doi: 10.1136/bmjopen-2019-033649
pmc: PMC7228510
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e033649

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Harm Reduct J. 2016 Oct 7;13(1):26
pubmed: 27717364
Lancet. 2010 Aug 14;376(9740):532-9
pubmed: 20638713
J Acquir Immune Defic Syndr. 2017 May 1;75(1):35-44
pubmed: 28225437
HIV Med. 2011 Jul;12(6):352-60
pubmed: 21059167
Lancet HIV. 2015 Mar;2(3):e92-7
pubmed: 25780802
Health Soc Care Community. 2004 Nov;12(6):475-87
pubmed: 15717895
Soc Sci Med. 1991;32(6):705-14
pubmed: 2035047
Res Nurs Health. 2001 Dec;24(6):518-29
pubmed: 11746080
Lancet. 2006 Aug 5;368(9534):531-6
pubmed: 16890841
Addiction. 1993 Jun;88(6):791-804
pubmed: 8329970
J Acquir Immune Defic Syndr. 2013 May 1;63(1):112-9
pubmed: 23392459
AIDS Res Hum Retroviruses. 2016 Feb;32(2):148-54
pubmed: 26670218
J Adolesc Health. 2007 Jan;40(1):96-8
pubmed: 17185215
J Int AIDS Soc. 2015 Oct 07;18:20261
pubmed: 26449273
BMJ. 2009 Apr 30;338:b1649
pubmed: 19406887
Qual Life Res. 2004 Dec;13(10):1659-70
pubmed: 15651537
Int J Epidemiol. 2014 Aug;43(4):1073-81
pubmed: 24695113
J Subst Abuse Treat. 2007 Mar;32(2):189-98
pubmed: 17306727
Ann Intern Med. 2008 Sep 2;149(5):289-99
pubmed: 18765698
JAMA. 1998 Aug 12;280(6):547-9
pubmed: 9707146
Addiction. 1995 Nov;90(11):1479-85
pubmed: 8528033
Qual Life Res. 1997 Aug;6(6):561-71
pubmed: 9330555
J Acquir Immune Defic Syndr. 2006 Apr 1;41(4):486-92
pubmed: 16652058
J Health Psychol. 1997 Jul;2(3):335-51
pubmed: 22013026
J Nurs Meas. 1993 Winter;1(2):165-78
pubmed: 7850498
BMC Infect Dis. 2016 Oct 21;16(1):590
pubmed: 27769246
N Engl J Med. 2011 Aug 11;365(6):493-505
pubmed: 21767103
Addict Behav. 1982;7(4):363-71
pubmed: 7183189
Med Care. 1998 Feb;36(2):138-54
pubmed: 9475469
PLoS One. 2012;7(7):e40793
pubmed: 22829885
Soc Sci Med. 2005 Oct;61(7):1576-96
pubmed: 16005789
Int J Drug Policy. 2010 Jan;21(1):4-9
pubmed: 19747811
J Infect. 2006 Apr;52(4):233-6
pubmed: 16169594
PLoS One. 2014 Dec 26;9(12):e115277
pubmed: 25541682
AIDS Patient Care STDS. 2012 Jan;26(1):60-7
pubmed: 22107040
J Behav Med. 2007 Oct;30(5):359-70
pubmed: 17588200
AIDS Care. 2008 Jul;20(6):615-24
pubmed: 18576163
Health Educ Res. 2008 Feb;23(1):106-14
pubmed: 17322572
AIDS Patient Care STDS. 2005 May;19(5):306-16
pubmed: 15916493

Auteurs

Andrea Bever (A)

British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.

Kate Salters (K)

British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada ksalters@cfenet.ubc.ca.
Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.

Clara Tam (C)

British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.

D M Moore (DM)

British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
University of British Columbia, Vancouver, British Columbia, Canada.

Paul Sereda (P)

British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.

Lu Wang (L)

British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.

Tim Wesseling (T)

British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.

Sean Grieve (S)

British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.

Brittany Bingham (B)

Aboriginal Health Program, Vancouver Coastal Health Authority, Vancouver, British Columbia, Canada.

Rolando Barrios (R)

British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
University of British Columbia, Vancouver, British Columbia, Canada.
Vancouver Community Health Services, Vancouver Coastal Health, Vancouver, British Columbia, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH